The needle-free drug delivery device market is expected to grow from US$ 14.76 million in 2023 to US$ 2842 million by 2031; it is anticipated to record a CAGR of 8.5% from 2024 to 2031.

Needle-free drug deliveries are taken in the form of power sprays, jet injectors, inhalers, and skin patches. Needle-free technology reduces patient concern about using needles. Needle-free devices are effective injections for a wide range of drugs and are bioequivalent to needles. Advantages of needle-free delivery devices include less pain, fast injection, no needle disposal issue, and can be self-administered. Thus, the benefits of needle-free drug delivery devices over conventional needles and syringes are mainly responsible for the increasing demand for needle-free drug delivery devices.

Rising Prevalence of Chronic Diseases and Lifestyle Disorders drives the Needle-Free Drug Delivery Device Market Growth.

Chronic diseases such as heart disease, diabetes, and cancer are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention (CDC), ~38.4 million people in America were suffering from diabetes in 2021. To control the incidence of diabetes, insulin is injected through the subcutaneous layer at regular intervals. Due to an increase in the prevalence of diabetes, the demand for insulin injections is also growing. According to the "Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study," a large-scale multinational study published in 2021, ~40% of 73,076 adults surveyed from 33 countries in the world were suffering from a functional gastrointestinal disorder (GFID). Age-related gastrointestinal problems are more common in the elderly population, aged 64 and above. Per the study titled "Gastrointestinal problem among Indian adults: Evidence from Longitudinal Aging Study in India," published in 2022, self-reported gastrointestinal disorders prevalence was reported at ~18%. The study also mentions that varying rates of gastrointestinal problems have been observed across the world, ranging from 14% in Iran to 54% in some western countries. Cardiovascular diseases (CVDs), especially the cases associated with hectic lifestyles, are a significant cause of mortality globally. According to the International Diabetes Federation (IDF), 537 million people worldwide, aged 20-79, had diabetes in 2021, and the number is estimated to rise to 783 million by 2045. Additionally, diabetes was the cause of 6.7 million deaths worldwide in 2021. According to the Neurological Alliance, ~14.7 million neurological cases were registered in 2019, with at least 1 in 6 people suffering from 1 or more neurological conditions. Increasing prevalence of chronic diseases and increasing requirement of various needle-free drug delivery systems is fueling the growth of the market.

Based on geography, the needle-free drug delivery device market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the biggest contributor to the global needle-free drug delivery device market growth. Asia Pacific is predicted to show the highest CAGR in the market during 2024-2031. North America dominated the needle-free drug delivery devices market in 2023. The market growth in North America is characterized by increased demand for rare disease medications from biopharmaceutical and biotechnology companies, the presence of key market players, an increase in product launches, a rise in the burden of needle stick injuries, and extensive R&D conducted by academic and research institutes and pharmaceutical and biotechnology companies.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and National Library of Medicine (NLM) are a few key primary and secondary sources referred to while preparing the report on the needle-free drug delivery device market.